-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is original for Translational Medicine.
Please indicate the source when reprinting.
Author: Jasmine Introduction: The discovery of rare mutations in clinical samples is of great significance in many fields such as biomedicine and diagnostics.
Current technologies require extensive sequencing to find low-abundance mutations of DNA fragments, a research team at MIT and Harvard has developed a new technique called MAESTRO that can accurately and efficiently identify thousands of DNA mutations in patient blood samples with a small amount of sequencing
.
A team of researchers at MIT and Harvard has developed a new technique called MAESTRO that can accurately and efficiently identify thousands of DNA mutations in patient blood samples with a small amount of sequencing
.
The method could be used to detect residual cancer in patients, not only alerting doctors to disease recurrence in a timely manner, but also at a lower cost than current technology
.
The study, published this week in the journal Nature Biomedical Engineering, is titled: "Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth
.
"
"Finding rare mutations in clinical samples has important implications in many fields, including biomedicine and diagnostics," explains co-senior author Viktor Adalsteinson
.
"Current technologies require extensive sequencing to find low-abundance DNA fragments, whereas MAESTRO is sensitive enough to find thousands of mutations with 100-fold less sequencing
.
" https://doi.
org/10.
1038/s41551-022 -00855-9 Searching for cancer DNA In cancer patients, tumor cells release some of their own DNA fragments into the bloodstream, and these DNA fragments from diseased tissue are significantly mutated
.
But any tumor DNA in a blood sample is only a tiny fraction floating in the ocean of healthy genetic material
.
Accurately detecting this rare amount of DNA is a challenge, especially looking for the small number of tumor cells left behind after cancer treatment (called "minimum residual disease," or MRD)
.
"We see a need for higher sensitivity," Adalsteinsson said.
"Our
team
has been working on techniques to address this
.
" The team has previously successfully detected small residuals in blood samples by scanning hundreds of cancer mutations cancer DNA
.
Scanning thousands of mutations can further improve MRD detection rates, but this often requires extensive sequencing to provide accurate results
.
MAESTRO, short for "minor allele enriched sequencing through recognition oligonucleotides", is a more efficient method for detecting low-frequency mutations
.
How does MAESTRO work? To use MAESTRO, researchers first sequence a patient's tumor biopsy to see what the mutation is like
.
Armed with this information, they can create specialized molecular probes that will bind only to tumor-associated DNA sequences
.
The scientists added molecular probes to cell-free DNA in blood samples and then washed away unbound DNA, enabling sequencers to identify rare cancer mutations from the samples
.
In this study, MAESTRO performed as well as conventional sequencing methods at detecting hundreds of low-abundance mutations, while discovering the majority of mutations while requiring far fewer resources
.
In addition, MAESTRO enabled the team to increase the search to 10,000 mutations at low cost, greatly improving detection
.
The researchers also re-examined patient samples analyzed using their traditional method
.
Using MAESTRO, they found more mutations from each blood sample tested, facilitating the detection of MRD after cancer treatment
.
MAESTRO combines the advantages of depth and breadth in a single detection, which opens up the possibility of detecting MRD earlier
.
New methods can make DNA sequencing more powerful and will have important implications for basic research and, in the future, clinical care
.
Going forward, the team is continuing to build a suite of technologies to reduce costs and increase the sensitivity of DNA tests for early detection of patients who need additional treatment to prevent relapse
.
Reference: https://medicalxpress.
com/news/2022-03-technique-cancer-dna-blood.
html Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment plans
.
For health guidance, please go to a regular hospital for treatment
.
Recommendation·Activity Click the text to view the details.
March 24th 19:00-20:30 Online Multiple Myeloma Research Progress and Application of MRD March 30th 19:00-21:00 Online Proteomics Frontiers and Advances Innovative Technology Outlook Webinar March 31st 19:00-21:00 Online Sharing of Global Technology | Tumor Precision Diagnosis Innovation and Development Webinar (coming soon) April 14th 09:00-18:00 Beijing Third 2018 Single-Cell Sequencing Technology Application Forum (coming soon) April 20, 09:00-18:00 How to improve the efficiency of new macromolecular drug research and development from basic experiments (coming soon)
Please indicate the source when reprinting.
Author: Jasmine Introduction: The discovery of rare mutations in clinical samples is of great significance in many fields such as biomedicine and diagnostics.
Current technologies require extensive sequencing to find low-abundance mutations of DNA fragments, a research team at MIT and Harvard has developed a new technique called MAESTRO that can accurately and efficiently identify thousands of DNA mutations in patient blood samples with a small amount of sequencing
.
A team of researchers at MIT and Harvard has developed a new technique called MAESTRO that can accurately and efficiently identify thousands of DNA mutations in patient blood samples with a small amount of sequencing
.
The method could be used to detect residual cancer in patients, not only alerting doctors to disease recurrence in a timely manner, but also at a lower cost than current technology
.
The study, published this week in the journal Nature Biomedical Engineering, is titled: "Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth
.
"
"Finding rare mutations in clinical samples has important implications in many fields, including biomedicine and diagnostics," explains co-senior author Viktor Adalsteinson
.
"Current technologies require extensive sequencing to find low-abundance DNA fragments, whereas MAESTRO is sensitive enough to find thousands of mutations with 100-fold less sequencing
.
" https://doi.
org/10.
1038/s41551-022 -00855-9 Searching for cancer DNA In cancer patients, tumor cells release some of their own DNA fragments into the bloodstream, and these DNA fragments from diseased tissue are significantly mutated
.
But any tumor DNA in a blood sample is only a tiny fraction floating in the ocean of healthy genetic material
.
Accurately detecting this rare amount of DNA is a challenge, especially looking for the small number of tumor cells left behind after cancer treatment (called "minimum residual disease," or MRD)
.
"We see a need for higher sensitivity," Adalsteinsson said.
"Our
team
has been working on techniques to address this
.
" The team has previously successfully detected small residuals in blood samples by scanning hundreds of cancer mutations cancer DNA
.
Scanning thousands of mutations can further improve MRD detection rates, but this often requires extensive sequencing to provide accurate results
.
MAESTRO, short for "minor allele enriched sequencing through recognition oligonucleotides", is a more efficient method for detecting low-frequency mutations
.
How does MAESTRO work? To use MAESTRO, researchers first sequence a patient's tumor biopsy to see what the mutation is like
.
Armed with this information, they can create specialized molecular probes that will bind only to tumor-associated DNA sequences
.
The scientists added molecular probes to cell-free DNA in blood samples and then washed away unbound DNA, enabling sequencers to identify rare cancer mutations from the samples
.
In this study, MAESTRO performed as well as conventional sequencing methods at detecting hundreds of low-abundance mutations, while discovering the majority of mutations while requiring far fewer resources
.
In addition, MAESTRO enabled the team to increase the search to 10,000 mutations at low cost, greatly improving detection
.
The researchers also re-examined patient samples analyzed using their traditional method
.
Using MAESTRO, they found more mutations from each blood sample tested, facilitating the detection of MRD after cancer treatment
.
MAESTRO combines the advantages of depth and breadth in a single detection, which opens up the possibility of detecting MRD earlier
.
New methods can make DNA sequencing more powerful and will have important implications for basic research and, in the future, clinical care
.
Going forward, the team is continuing to build a suite of technologies to reduce costs and increase the sensitivity of DNA tests for early detection of patients who need additional treatment to prevent relapse
.
Reference: https://medicalxpress.
com/news/2022-03-technique-cancer-dna-blood.
html Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment plans
.
For health guidance, please go to a regular hospital for treatment
.
Recommendation·Activity Click the text to view the details.
March 24th 19:00-20:30 Online Multiple Myeloma Research Progress and Application of MRD March 30th 19:00-21:00 Online Proteomics Frontiers and Advances Innovative Technology Outlook Webinar March 31st 19:00-21:00 Online Sharing of Global Technology | Tumor Precision Diagnosis Innovation and Development Webinar (coming soon) April 14th 09:00-18:00 Beijing Third 2018 Single-Cell Sequencing Technology Application Forum (coming soon) April 20, 09:00-18:00 How to improve the efficiency of new macromolecular drug research and development from basic experiments (coming soon)
